Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.72
Bid: 3.20
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.64 (20.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.72
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Saori Trial Update

1 Mar 2021 07:00

RNS Number : 5960Q
Plant Health Care PLC
01 March 2021
 

Reach

1 March 2021

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Saori Trial Update

Preliminary results for the Prevention and Treatment of Asian Soybean Rust in Brazil

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, provides an update on its most advanced proprietary soybean seed treatment for the prevention and treatment of Asian Soybean Rust ("ASR").

 

Highlights

· PHC279 has been named "Saori™" for Brazil soybeans, to build brand recognition in the marketplace

· Sixteen field trials successfully completed

· Saori consistently improved control of ASR

· 6x RoI demonstrated for Brazilian soybean growers

· Initial commercial discussions are under way with distributors

· Commercial launch on track for the second half of 2021

 

Background

PHC279 is the Company's first product from its PREtec platform to be commercialised. To aid brand recognition in the marketplace, PHC279 has been named "Saori™" for seed treatment in Brazil soybeans.

Brazil is the world's leading soybean producer with more than 38 million hectares (95 million acres) planted in the current season. ASR, caused by the fungus Phakopsora pachyrhizi, is a devastating disease which can lead to crop yield loss of up to 90%. Brazilian soybean farmers spent US$2.85 billion on disease control in the 2019/20 season, approximately 90% of which was for ASR control.

Saori is the first PREtec peptide approved in Brazil. PREtec peptides represent a novel class of technology which stimulate the plant to defend itself. Derived from natural proteins, PREtec is an environmentally friendly approach to protecting crops and is compatible with mainstream agricultural practices.

Testing Protocol

To date, the Company has completed 16 trials using commercial volumes of Saori and has 34 trials ongoing this season. PHC and its partners have been visiting the ongoing soybean trials across Brazil. Preliminary results suggest significantly improved early plant growth and enhanced early season disease control in the Saori treated fields.

Preliminary Test Results

Across all 16 trials, Saori consistently improved control of ASR. Saori shows potential as a novel tool for integrated pest management systems, reducing the use of potentially less safe agrochemicals during the trial period.

From a value proposition perspective, Saori demonstrated the potential to deliver disease control and increased crop yield worth an average of about US$85/ha for Brazilian soybean growers, delivering a Return on Investment ("RoI") of 6x or more.

PHC has now begun commercial discussions with leading crop protection companies in Brazil, many of which have planted their own soybean trials to independently confirm the performance of Saori.

The Company is planning the commercial launch of Saori during the second half of 2021. Initial sales will specifically focus on early adopters of novel technologies within the sustainable agricultural markets. Significant penetration of a market estimated to be worth approximately US$2.56bn per annum is expected over the following three to five years.

Chris Richards, CEO of Plant Health Care said, "Saori has the potential to be a truly disruptive and sustainable technology in soybeans, boosting crop growth while improving disease control. It is not only highly cost-effective, but also delivers a big step in improving the sustainability of soybean production. While drought delayed planting in many areas of Brazil, Saori is demonstrating encouraging performance during the current soybean season; we are already seeing increased vigour and early season disease control. We look forward with confidence to the initial commercial launch of Saori in the second half of 2021. Outside Brazil, we are preparing to launch PREtec products to markets in the U.S. and other countries, initially targeting markets with opportunities greater than $5 billion."

For further information, please contact:

Plant Health Care plc

Chris Richards, CEO, Tel: +1 919 926 1600

 

Arden Partners plc - Nomad & Broker

John Llewellyn-Lloyd / Ben Cryer Tel: +44 (0) 20 7614 5900

 

Vox Markets - Digital investor relations

Paul Cornelius / Kat Perez Tel; +44 (0) 7866 384707

 

Company website: http://www.planthealthcare.com

 

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRALQLLLFLLFBBE
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.